Transthoracic closure of XXXX and @entity1757 without @entity1167 .

@entity1 @entity713 @entity117 @entity1757 @entity886 @entity299 @entity1167 @entity118 @entity130
UNASSIGNED: The minimally invasive surgical transthoracic occlusion of an @entity118 ( @entity118 ) or a @entity1757 ( @entity1757 ) is an increasingly widespread alternative treatment for @entity299 . The aim of this study is to summarize our clinical experience with minimally invasive surgical transthoracic occlusion of @entity118 and @entity1757 without @entity1167 ( @entity1167 ). Between April 2011 and October 2012, 27 @entity1 with @entity118 and 95 @entity1 with @entity1757 (78 @entity1 and 44 @entity1 ) were considered for minimally invasive surgical transthoracic occlusion without @entity1167 . A small infrasternal incision (2.0-4.0 cm) was made under general anesthesia, under transesophageal echocardiography (TEE) guidance; the @entity118 and @entity1757 were closed by using an appropriate occluder; and TEE was performed simultaneously to demonstrate the position of the device, any residual shunting, or encroachment on the @entity886 . Successful transthoracic occlusion was performed in all 122 @entity1 without complications. No complications such as third-degree @entity713 and residual shunting occurred after the procedures. The ventilation time was 2.2    1.2 h, and the average length of hospital stay was 4.7    1.7 days. All @entity1 received @entity117 at 3 mg  kg(-1)  day(-1) (maximum 100 mg/day) 24 h after the procedure. Minimally invasive surgical transthoracic occlusion without @entity1167 is a new treatment that has many advantages such as causing little @entity130 , promoting quick recovery, having less complications, and avoiding radiation damage. However, the appropriate selection of @entity1 is still key to improving the success rate of the operation.
